지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Endoscopic mucosal resection (EMR) has been accepted as one of the standard treatments of early gastric cancer (EGC) with a negligible risk of lymph node metastasis. EMR is similar to surgery in efficacy but less invasive and more cost-effective. And it allows accurate histological staging of the tumor, which is critical in deciding whether additional treatment is necessary.
Standard indications for EMR of EGC include differentiated elevated cancer less than 2 cm in size and depressed cancer without ulceration less than 1 cm in size. Recently, expanded indication has been proposed in Japan to cover other lesions with a negligible risk of lymph node metastasis, which include larger lesions and lesions with ulceration. With the development of endoscopic submucosal dissection (ESD), en bloc resection of larger and even ulcerative lesion is possible. However, the lack of long-term data makes it difficult to widely accept expanded indication. More long-term studies about therapeutic outcomes are needed to fully bolster the safety and establish correct therapeutic role of ESD in treatment of EGC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청이 논문의 저자 정보
최근 본 자료
댓글(0)
0